Navigation Links
Mylan Announces Completion of Transdermal Patch Facility Expansion Project in St. Albans, Vt.
Date:9/4/2013

ST. ALBANS, Vt., Sept. 4, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the completion of an 85,000 square foot, three-story expansion project at its transdermal patch facility, operated by Mylan Technologies Inc. (MTI), in St. Albans, Vt. Through Mylan's investment, including funding for expanded research and development (R&D) capabilities and additional manufacturing and laboratory space, the company is in the process of adding more than 160 new positions to its St. Albans-based workforce. MTI is a proven leader in transdermal drug delivery systems – patches that deliver medication through the skin – and related technologies.

In conjunction with the expansion project, Mylan today hosted a ribbon-cutting ceremony to commemorate the occasion. Vermont Governor Peter Shumlin as well as a number of local officials, community members and employees, attended the event.

Mylan CEO Heather Bresch said: "Mylan's investment in the ongoing growth of our transdermal franchise demonstrates our continued commitment to and confidence in our ability to provide complex generic and interchangeable products and innovative delivery alternatives, such as transdermals. Through this expansion, MTI will continue to play a critical role in the expansion and diversification of Mylan's global product portfolio, especially when it comes to difficult-to-develop and –manufacture products. I would like to thank Governor Shumlin as well as the city of St. Albans for their ongoing support of this project. Importantly, I would also like to recognize Mylan's more than 590 employees in Vermont for their hard work and dedication to our continued success."

The 14-month expansion project has increased MTI's total operating space to more than 391,000 square feet. Since becoming a part of the Mylan manufacturing network more than 20 years ago, MTI has developed a number of branded and generic transdermal products available to patients in markets around the world, including the U.S., Canada, Europe, Japan, New Zealand and Australia.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com


'/>"/>
SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Acquisition of Agila Receives Approval from Indias Foreign Investment Promotion Board and Cabinet Committee on Economic Affairs
2. Mylan Confirms Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
3. Mylan Reports a 13% Increase in Second Quarter 2013 Adjusted Diluted EPS to $0.68
4. Third Circuit Rules in Mylans Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylans Breach of Contract Claim Against GSK to Trial
5. Mylan to Host Investor Day on Aug. 1, 2013 in New York City
6. Roger Graham Named President of Mylan Specialty
7. Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
8. Mylan to Speak at the Goldman Sachs 34th Annual Global Healthcare Conference
9. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix
10. Mylan Specialty L.P. Announces Partnership with Baseball Teams Across Country to Raise Awareness of Potentially Life-Threatening Allergies
11. Presenting Sponsor Mylan Specialty L.P. Calls on Communities Nationwide to Join The Food Allergy Research & Education (FARE) Walk for Food Allergy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/9/2020)... ... April 09, 2020 , ... ... is proud to announce its strategic partnership alliance with X.Labs, a California ... safety and security. SDS will be the premier distributor of X.Labs’ latest ...
(Date:4/9/2020)... ... 2020 , ... Unprecedented times call for creative ways to stay connected with ... for generations, invites folks to put the “social” in social distancing and reconnect online ... a fun trivia party at home or online, http://www.readsalads.com/gamenight gives fans a ...
(Date:4/9/2020)... ... April 09, 2020 , ... ... Academy ( https://suntuityuniversity.com/airworks-academy/ ), is offering free webinars to introduce public safety ... the COVID-19 Pandemic. , Leveraging Suntuity University’s Learning Management Systems and ...
Breaking Medicine Technology:
(Date:4/9/2020)... ... April 09, 2020 , ... T1 Payments , a leader in high-risk ... shelter residents, and anyone who may be experiencing safety issues at home during this ... many families and individuals struggle with increased financial, emotional, and economic instability during the ...
(Date:4/7/2020)... ... ... Black Jaguar-White Tiger Foundation, the global non-profit is launching a line of ... consists of a chewable tablet and tincture available in a morning and night dosage. ... “It is my great Honor, to finally introduce to you, what I consider to ...
(Date:4/5/2020)... ... April 04, 2020 , ... MyAdvisor, a ... uniting with the Yellow Ribbon Fund (YRF) to offer mental health and care ... continuing an ongoing partnership to launch a new initiative throughout the global COVID-19 ...
(Date:4/2/2020)... ... April 02, 2020 , ... FDA CDS Software Regulation:, ... 7, 2020, 1:30-3:00 p.m. EDT, https://www.fdanews.com/cdssoftwareregulation , *NEW: ... guide clinical management of the Coronavirus.* , Is one’s software regulated as a ...
(Date:4/2/2020)... NEW ORLEANS (PRWEB) , ... April 02, 2020 ... ... opioids while fetuses in their mother’s womb are encouraging their parents, grandparents, and ... compensation from Purdue—reportedly up to $6 billion in funds will be made available ...
Breaking Medicine News(10 mins):